Advertisement
Document › Details
IP Group plc. (5/15/18). "Press Release: IP Group and Johns Hopkins Collaboration Funds Cancer Therapeutic Start-up".
Organisation | IP Group plc (LSE: IPO) | |
Group | IP Group (Group) | |
Organisation 2 | Johns Hopkins University | |
Product | small-molecule cancer drug | |
Product 2 | drug development | |
IP Group (LSE: IPO), an intellectual property commercialization company, announces that it has funded its first company in partnership with Johns Hopkins University. Lorem Therapeutics will be focused on developing early-stage therapeutics, bridging the gap from drug discovery to Investigative New Drug (IND) status, specifically novel small molecule prodrugs for cancer indications.
Lorem is led by Professor Barbara Slusher, PhD. MAS, who has an extensive track record of bringing lead compounds from drug discovery through clinical development. Dr. Slusher directs Johns Hopkins Drug Discovery, the largest integrated drug discovery program at the University, with a veteran team of medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetic and drug metabolism experts. The team is engaged in identifying novel drug targets arising from the faculty’s research and translating them into new drug therapies for clinical development.
Christy Wyskiel, the head of Johns Hopkins Technology Ventures, the university’s intellectual property administration center, said: “The relationship Johns Hopkins has forged with IP Group aims to facilitate one of our institution’s longstanding missions - to bring the benefits of discovery to the world. The support provided to early-stage technologies through this model of venture creation has the potential to accelerate the transformation of promising research into impactful products and services.”
Michael Burychka, Chief Executive Officer, IP Group North America, said: “We are excited to announce the first investment from our collaboration with Johns Hopkins University. IP Group is committed to supporting scientific discovery and is thrilled to work with Dr. Slusher. We look forward to building upon our relationship with Johns Hopkins and continuing to invest in novel science being developed at the university.”
Accompanying the initial funding, Lorem Therapeutics will receive support from FastForward, a coordinated suite of resources managed by Johns Hopkins Technology Ventures that provides more than 100 startups with access to affordable space, services and funding opportunities.
Dr. Barbara Slusher said, “I am delighted to have the support of IP Group, Johns Hopkins Technology Ventures and FastForward as we launch this exciting venture. IP Group’s commercial expertise and initial funding as well as FastForward’s ongoing support will play a critical role in helping us accelerate and enhance our drug discovery efforts around critical cancer indications.”
For more information, please contact:
IP Group, North America
www.ipgroup-inc.com
Frank De Maria
fdemaria@s360group.com
+1 347 647 0284
IP Group plc
www.ipgroupplc.com
Liz Vaughan-Adams, Communications
liz.vadams@ipgroupplc.com
+44 (0) 20 7444 0062/+44 (0) 7979 853802
Notes for editors
About IP Group
IP Group is a leading intellectual property commercialization company focused on evolving great ideas from its partner universities into world-changing businesses. The Group pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital, scientific insight and the supporting infrastructure.
In North America, IP Group works in close partnership with a select group of universities and U.S. Department of Energy Laboratories to identify groundbreaking technologies, rooted in hard science, which have the most promising commercial potential.
IP Group, which is listed on the Main Market of the London Stock Exchange under the symbol IPO, has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology.
For more information, please visit our US website at www.ipgroup-inc.com or our corporate website at www.ipgroupplc.com.
ENDS
Record changed: 2023-06-05 |
Advertisement
More documents for IP Group (Group)
- [1] Elsamogen Ltd.. (5/18/22). "Press Release: BGF, Scottish National Investment Bank and Scottish Enterprise Join Forces to Invest £8m in Aberdeen Biologics Company Elasmogen". Aberdeen....
- [2] Semarion Ltd.. (2/22/22). "Press Release: Semarion Raises £2.14m Seed Funding to Commercialise Cell Assaying Platform". Cambridge....
- [3] Boehringer Ingelheim. (10/19/21). "Press Release: Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis". Paris....
- [4] IP Group plc. (5/4/21). "Press Release: Portfolio Company Oxford Nanopore Technologies Raises £195m in New Investment"....
- [5] Mogrify Ltd.. (5/4/21). "Press Release: Mogrify Completes Series A financing Totaling $33 Million USD". Cambridge....
- [6] CytoSeek Ltd.. (3/16/21). "Press Release: CytoSeek Raises £3.57M ($5M) to Advance Its Mission to Develop the Next Generation of Cell Therapies for Cancer". Bristol....
- [7] PredictImmune Ltd.. (7/30/19). "Press Release: PredictImmune Closes Series B Funding Round, Raising £10M to Further Accelerate Global Commercial Expansion and Support Expanding Product Pipeline". Cambridge....
- [8] Genomics plc. (8/30/18). "Press Release: Genomics plc Raises £25 million in Series B Round to Advance Its Use of Human Genetics and Data Science in Drug Discovery". Oxford....
- [9] Boehringer Ingelheim. (8/6/18). "Press Release: Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis". Ingelhei...
- [10] IP Group plc. (2/1/17). "Press Release: Completion of Acquisition of Parkwalk"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top